Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: Gerald Underwood who wrote (49)	10/26/1999 11:22:00 AM
From: Marty	Read Replies (1) \| Respond to of 204

Here's the press release from the Neuroscience Conference. It seems to me that nine presentations at one conference is an awful lot. I wonder if it was the Society that asked for that many. The abstracts from the conference should be on the website soon. Tuesday October 26, 9:31 am Eastern Time Company Press Release SOURCE: NeoTherapeutics, Inc. NeoTherapeutics' Research the Subject of Nine Presentations at the Society for Neuroscience Conference IRVINE, Calif., Oct. 26 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news, NEOTW - news) announced today that nine presentations on its lead drug for the treatment of Alzheimer's disease, NEOTROFIN(TM) (AIT-082), were presented at the 29th Annual Meeting of the Society for Neuroscience, held this week in Miami Beach, Florida. The Society for Neuroscience Annual Meeting brings together over 20,000 neuroscientists from around the world to share the latest research findings in the dynamic field of neuroscience. Of the nine research presentations, two cover research conducted by NeoTherapeutics' internal scientists and seven presentations are by collaborating researchers from universities in the United States, Canada and Italy. The presentations all were directed to further the understanding of the effects of NEOTROFIN(TM) on nerve regeneration, nerve impulse transmission and protection against nerve injury. Abstracts of these presentations may be seen in the technology section of NeoTherapeutics, Inc.'s Web site at: www.neotherapeutics.com. Some of the NEOTROFIN(TM) presentations showcased at this important international meeting involve nerve repair after spinal cord injury, protection against nerve damage under stroke-like conditions, enhanced synaptic transmission, memory improvement, and the drug's ability to cross the blood-brain barrier. This variety in the research further highlights the uniqueness of NEOTROFIN(TM) from other drugs currently in development for Alzheimer's disease. ''Exciting new research on NEOTROFIN(TM) is being presented by our own researchers and outstanding scientists from collaborating universities,'' said Dr. Alvin J. Glasky, NeoTherapeutics' President, CEO and Chief Scientific Officer. ''The research data presented this week illustrates the importance of NEOTROFIN's actions in enhancing the body's response to nerve degeneration and injury both in the brain and spinal cord. The breadth of research findings on NEOTROFIN(TM) presented here illustrates the importance of this drug for the treatment of serious diseases for which there may currently be no effective therapy.'' Current research being conducted at leading universities in the U.S. and around the world is now demonstrating the feasibility of nerve regeneration. Reports on nerve stem cells and their stimulation by neurotrophic factors to multiply, migrate and mature into functioning new nerves has now made the concept of nerve regeneration realizable. NEOTROFIN(TM) is being developed for nerve repair and regeneration, with Alzheimer's disease as its first clinical indication. Pre-clinical studies have demonstrated that NEOTROFIN(TM) causes the production of multiple natural nerve growth factors and restores function in animal models of memory decline, aging, brain injury, and spinal cord injury. Human clinical studies have demonstrated positive effects of NEOTROFIN(TM) on memory and behavioral function in patients with Alzheimer's disease. NeoTherapeutics' research program is focused on designing and developing small molecules capable of promoting nerve regeneration and repair for a range of neurological diseases and conditions such as Alzheimer's and Parkinson's diseases, stroke and spinal cord injury. Additional compounds in NeoTherapeutics' product pipeline address other health issues such as migraine and depression. For additional Company information, visit the NeoTherapeutics web site at www.neotherapeutics.com. This press release contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. For more information, contact investment community, Carol Gruetter of NeoTherapeutics, Inc., 949-788-6700, ext., 236, or cgruetter@neotherapeutics.com; or media, Kelly Finley of Halsted Communications, Inc., 800-600-7111 ext., 250, or 323-225-1835, or kfinley@halsted.com, for NeoTherapeutics, Inc. SOURCE: NeoTherapeutics, Inc.